Filippo Pietrantonio, MD, discusses updated results from the phase 1b/2 OrigAMI-1 trial, which showed that amivantamab with or without chemotherapy demonstrated durable antitumor activity among patients with right-sided metastatic colorectal...
Filippo Pietrantonio, MD, discusses updated results from the phase 1b/2 OrigAMI-1 trial, which showed that amivantamab with or without chemotherapy demonstrated durable antitumor activity among patients with right-sided metastatic colorectal...
Filippo Pietrantonio, MD,...